Samsung Biologics Co.,Ltd. (KRX:207940)

Samsung Biologics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Revenue	4,557,000	4,547,322	3,694,589	3,001,295	1,568,007
Other Revenue	-	-	-	-0	-
Revenue	4,557,000	4,547,322	3,694,589	3,001,295	1,568,007
Revenue Growth (YoY)	0.21%	23.08%	23.10%	91.41%	34.62%
Cost of Revenue	2,040,000	2,273,151	1,900,080	1,540,526	844,657
Gross Profit	2,517,000	2,274,171	1,794,509	1,460,769	723,350
Selling, General & Admin	447,000	758,510	535,421	380,456	169,630
Research & Development	-	144,649	81,588	45,884	954.22
Amortization of Goodwill & Intangibles	-	13,629	9,977	7,700	4,572
Other Operating Expenses	-	11,145	10,339	7,448	1,804
Operating Expenses	447,000	954,119	680,829	477,142	186,040
Operating Income	2,070,000	1,320,052	1,113,680	983,627	537,309
Interest Expense	-	-50,057	-81,596	-64,064	-14,707
Interest & Investment Income	-	63,839	95,650	53,293	9,656
Earnings From Equity Investments	-	2,660	-499.42	27,260	13,853
Currency Exchange Gain (Loss)	-	77,140	-11,186	-63,503	17,874
Other Non Operating Income (Expenses)	49,000	19,789	2,652	2,347	4,494
EBT Excluding Unusual Items	2,119,000	1,433,423	1,118,701	938,960	568,479
Gain (Loss) on Sale of Investments	-	597.28	5,152	72,653	269.12
Gain (Loss) on Sale of Assets	-	-2,199	-3,866	-2,588	-7,466
Asset Writedown	-	-61,770	-	-	-
Pretax Income	2,119,000	1,370,052	1,119,987	1,009,025	561,283
Income Tax Expense	505,000	286,736	262,296	210,968	167,693
Earnings From Continuing Operations	1,614,000	1,083,316	857,691	798,056	393,589
Earnings From Discontinued Operations	170,000	-	-	-	-
Net Income to Company	1,784,000	1,083,316	857,691	798,056	393,589
Net Income	1,784,000	1,083,316	857,691	798,056	393,589
Net Income to Common	1,784,000	1,083,316	857,691	798,056	393,589
Net Income Growth	64.68%	26.31%	7.47%	102.76%	63.33%
Shares Outstanding (Basic)	46	46	46	45	43
Shares Outstanding (Diluted)	46	46	46	45	43
Shares Change (YoY)	-	-	1.95%	5.51%	-
EPS (Basic)	38538.85	23402.33	18528.27	17592.79	9146.19
EPS (Diluted)	38538.85	23402.33	18528.27	17577.11	9146.19
EPS Growth	64.68%	26.31%	5.41%	92.18%	63.33%
Free Cash Flow	-	355,682	671,158	-3,792	48,343
Free Cash Flow Per Share	-	7683.62	14498.68	-83.52	1123.38
Gross Margin	55.23%	50.01%	48.57%	48.67%	46.13%
Operating Margin	45.42%	29.03%	30.14%	32.77%	34.27%
Profit Margin	39.15%	23.82%	23.21%	26.59%	25.10%
Free Cash Flow Margin	-	7.82%	18.17%	-0.13%	3.08%
EBITDA	-	1,919,154	1,603,462	1,291,892	699,098
EBITDA Margin	-	42.20%	43.40%	43.04%	44.59%
D&A For EBITDA	694,023	599,101	489,782	308,264	161,789
EBIT	2,070,000	1,320,052	1,113,680	983,627	537,309
EBIT Margin	45.42%	29.03%	30.14%	32.77%	34.27%
Effective Tax Rate	23.83%	20.93%	23.42%	20.91%	29.88%
Advertising Expenses	-	17,042	11,916	8,829	5,349

Source: S&P Global Market Intelligence. Standard template. Financial Sources.